# Argosy University

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/argosy-university/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 41 |
| Citations | 34,046 |
| City | Orange |
| Country | US |
| Description | Argosy University is a research organisation in Orange, US. OpenAlex records 1,114 works and 34,046 citations for it. 380 researchers list it as their most recent affiliation. |
| Homepage | https://www.argosy.edu/ |
| OpenAlex ID | https://openalex.org/I109780856 |
| Region | California |
| Researchers | 380 |
| ROR ID | https://ror.org/001p2e958 |
| Type | education |
| Works | 1,114 |

## University papers

- [Platinum Resistance: The Role of DNA Repair Pathways](https://scholariq.org/papers/platinum-resistance-the-role-of-dna-repair-pathways/)
- [Ovarian Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-2-2020-nccn-clinical-practice-guidelines-in-oncology/)
- [Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer](https://scholariq.org/papers/mirvetuximab-soravtansine-in-fr-positive-platinum-resistant-ovarian-cancer/)
- [NCCN Guidelines® Insights: Ovarian Cancer, Version 3.2022](https://scholariq.org/papers/nccn-guidelines-insights-ovarian-cancer-version-3-2022/)
- [Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer](https://scholariq.org/papers/weekly-vs-every-3-week-paclitaxel-and-carboplatin-for-ovarian-cancer/)
- [Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology](https://scholariq.org/papers/ovarian-cancer-version-1-2016-nccn-clinical-practice-guidelines-in-oncology/)
- [Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody–Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study](https://scholariq.org/papers/safety-and-activity-of-mirvetuximab-soravtansine-imgn853-a-folate-receptor-alpha/)
- [First-in-Human Study of AMG 820, a Monoclonal Anti-Colony-Stimulating Factor 1 Receptor Antibody, in Patients with Advanced Solid Tumors](https://scholariq.org/papers/first-in-human-study-of-amg-820-a-monoclonal-anti-colony-stimulating-factor-1/)
- [Ovarian Cancer, Version 3.2012](https://scholariq.org/papers/ovarian-cancer-version-3-2012/)
- [Uterine Neoplasms, Version 1.2014](https://scholariq.org/papers/uterine-neoplasms-version-1-2014/)
- [Rucaparib maintenance for newly diagnosed advanced ovarian cancer: interim overall survival, progression-free survival, and safety at 5 years of follow-up from the phase III ATHENA-MONO/GOG-3020/ENGOT-ov45 study](https://scholariq.org/papers/rucaparib-maintenance-for-newly-diagnosed-advanced-ovarian-cancer-interim/)

## University researchers

- [Lainie P. Martin](https://scholariq.org/researchers/lainie-p-martin/)

## University top topics

Showing 8 of 25.

- [Psychotherapy Techniques and Applications](https://scholariq.org/topics/psychotherapy-techniques-and-applications/)
- [Child and Adolescent Psychosocial and Emotional Development](https://scholariq.org/topics/child-and-adolescent-psychosocial-and-emotional-development/)
- [Counseling Practices and Supervision](https://scholariq.org/topics/counseling-practices-and-supervision/)
- [Counseling, Therapy, and Family Dynamics](https://scholariq.org/topics/counseling-therapy-and-family-dynamics/)
- [Attachment and Relationship Dynamics](https://scholariq.org/topics/attachment-and-relationship-dynamics/)
- [Eating Disorders and Behaviors](https://scholariq.org/topics/eating-disorders-and-behaviors/)
- [Attention Deficit Hyperactivity Disorder](https://scholariq.org/topics/attention-deficit-hyperactivity-disorder/)
- [Personality Disorders and Psychopathology](https://scholariq.org/topics/personality-disorders-and-psychopathology/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.